OMER News and Press, Omeros Corporation From 12/02/20

Omeros (OMER) +24.7% post-market after a rule from the Centers for Medicare & Medicaid Services showed the company's Omidria qualifies as a non-opioid pain management drug that functions as a surgical supply.According to Bloomberg, the ruling means Omidria will be excluded from packa...

Palm Beach, FL – November 19, 2020 – According to the American Cancer Society, the number of new acute myeloid leukemia cases is estimated to continue to grow in the U.S. due to a number of factors.  The rising prevalence of acute myeloid leukemia and unmet needs of the p...

Omeros (OMER) shares climb 7.5% after the company completes its rolling submission of its Biologics License Application to the FDA for narsoplimab for the treatment of a complication associated with stem cell transplantation.The company has requested priority review for the BLA, and appl...

-- Priority Review Requested -- Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell tra...

Omeros Corp (OMER) Q3 2020 Earnings Conference Call November 09, 2020, 16:30 ET Company Participants Jennifer Williams - IR Greg Demopulos - Co-Founder, Chairman, CEO & President Michael Jacobsen - CAO, VP, Finance & Treasurer Daniel Kirby - Chief Commercial Officer, VP & Head, Co...

Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders...

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m...

Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeut...

The following slide deck was published by Omeros Corporation in conjunction with this event. For further details see: Omeros (OMER) OMS906 Monoclonal Antibody Targeting MASP-3 - Slideshow

Omeros (OMER) has announced final data from its pivotal trial for narsoplimab (OMS721) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. Interim data from the study was reported in December ...